Finally, the functional significance of the newly identified Noxa1 mRNA in RVLM on age-dependent susceptibility of cardiovascular responses to tissue NO deficiency is validated by our findings that bilateral microinjection into RVLM of Lv-Noxa1-shRNA appreciably ameliorated hypertension, the exaggerated sympathetic vasomotor activity, and plasma NE levels evoked by l-NAME treatment in adult animals. This evidence concerns the gene NOXA1 and hypertensive disorder.